Opko Health Inc (NASDAQ: OPK) has moved into an exclusive worldwide agreement with CAMP4 Therapeutics Corporation. The two will embark on the manufacture, development, and commercialization of Therapeutics by utilizing the AntagoNAT technology.  Focusing on the AntagoNAT  This company describes AntagoNATs as the oligonucleotide compounds which target non-coding natural antisense transcripts, […]